Table of Content

1 Introduction 6
1.1 Industry Definition and Research Scope 6
1.1.1 Industry Definition 6
1.1.2 Research Scope 7
1.2 Research Methodology 10
1.2.1 Overview of Market Research Methodology 10
1.2.2 Market Assumption 11
1.2.3 Secondary Data 11
1.2.4 Primary Data 11
1.2.5 Data Filtration and Model Design 13
1.2.6 Market Size/Share Estimation 14
1.2.7 Research Limitations 15
1.3 Executive Summary 16

2 Market Overview and Dynamics 19
2.1 Market Size and Forecast 19
2.1.1 Impact of COVID-19 on World Economy 21
2.1.2 Impact of COVID-19 on the Market 24
2.2 Major Growth Drivers 26
2.3 Market Restraints and Challenges 29
2.4 Emerging Opportunities and Market Trends 32
2.5 Porter’s Fiver Forces Analysis 36

3 Segmentation of North America Market by Vaccine Type 40
3.1 Market Overview by Vaccine Type 40
3.2 Live/Attenuated Vaccines 42
3.3 Inactivated Vaccines 43
3.4 Subunit Vaccines 44
3.5 Toxoid Vaccines 45
3.6 Conjugate Vaccines 46
3.7 Recombinant Vector Vaccines 47
3.8 Other Vaccines 48

4 Segmentation of North America Market by Disease 49
4.1 Market Overview by Disease 49
4.2 Vaccines for Pneumococcal Disease 51
4.3 Vaccines for Poliovirus 52
4.4 Vaccines for Hepatitis 53
4.5 Vaccines for Influenza 54
4.6 Vaccines for Measles, Mumps, and Rubella (MMR) 55
4.7 Vaccines for Varicella 56
4.8 Vaccines for Human Papilloma Virus 57
4.9 Vaccines for COVID-19 58
4.10 Vaccines for Other Diseases 59

5 Segmentation of North America Market by Administration 60
5.1 Market Overview by Administration 60
5.2 Intramuscular Route 62
5.3 Subcutaneous Route 63
5.4 Oral Route 64
5.5 Intravenous Injection 65
5.6 Other Administration Routes 66

6 Segmentation of North America Market by Patient 67
6.1 Market Overview by Patient 67
6.2 Pediatric Vaccines 69
6.3 Adult Vaccines 71

7 North America Market 2019-2026 by Country 73
7.1 Overview of North America Market 73
7.2 U.S. 76
7.3 Canada 81
7.4 Mexico 84

8 Competitive Landscape 87
8.1 Overview of Key Vendors 87
8.2 New Product Launch, Partnership, Investment, and M&A 90
8.3 Company Profiles 91
AstraZeneca plc 91
Bavarian Nordic A/S 93
China National Biotec Group Company Ltd. 94
CSL Ltd. 95
Daiichi Sankyo Co. Ltd 96
Emergent BioSolutions Inc. 97
GlaxoSmithKline PLC 98
Johnson & Johnson 99
Merck & Co. 100
Novavax, Inc. 101
Pfizer Inc. 102
Sanofi SA 103
Takeda Pharmaceutical Co. Ltd 104

9 Investing in North America Market: Risk Assessment and Management 105
9.1 Risk Evaluation of North America Market 105
9.2 Critical Success Factors (CSFs) 108
Related Reports and Products 111
_



List of Figures


Figure 1. Research Method Flow Chart 10
Figure 2. Breakdown of Primary Research 12
Figure 3. Bottom-up Approach and Top-down Approach for Market Estimation 14
Figure 4. North America Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2019-2026 16
Figure 5. North America Preventive Vaccines Market, 2019-2026, $ mn 19
Figure 6. Development Stages of Preventive Vaccines 20
Figure 7. Impact of COVID-19 on Business 24
Figure 8. Primary Drivers and Impact Factors of North America Preventive Vaccines Market 26
Figure 9. Primary Restraints and Impact Factors of North America Preventive Vaccines Market 29
Figure 10. Investment Opportunity Analysis 33
Figure 11. Porter’s Fiver Forces Analysis of North America Preventive Vaccines Market 36
Figure 12. Breakdown of North America Preventive Vaccines Market by Vaccine Type, 2019-2026, % of Revenue 41
Figure 13. Contribution to North America 2020-2026 Cumulative Revenue by Vaccine Type, Value ($ mn) and Share (%) 41
Figure 14. North America Preventive Vaccines Market: Live/Attenuated Vaccines, 2016-2026, $ mn 42
Figure 15. North America Preventive Vaccines Market: Inactivated Vaccines, 2016-2026, $ mn 43
Figure 16. North America Preventive Vaccines Market: Subunit Vaccines, 2016-2026, $ mn 44
Figure 17. North America Preventive Vaccines Market: Toxoid Vaccines, 2016-2026, $ mn 45
Figure 18. North America Preventive Vaccines Market: Conjugate Vaccines, 2016-2026, $ mn 46
Figure 19. North America Preventive Vaccines Market: Recombinant Vector Vaccines, 2016-2026, $ mn 47
Figure 20. North America Preventive Vaccines Market: Other Vaccines, 2016-2026, $ mn 48
Figure 21. Breakdown of North America Preventive Vaccines Market by Disease, 2019-2026, % of Revenue 50
Figure 22. Contribution to North America 2020-2026 Cumulative Revenue by Disease, Value ($ mn) and Share (%) 50
Figure 23. North America Preventive Vaccines Market: Vaccines for Pneumococcal Disease, 2016-2026, $ mn 51
Figure 24. North America Preventive Vaccines Market: Vaccines for Poliovirus, 2016-2026, $ mn 52
Figure 25. North America Preventive Vaccines Market: Vaccines for Hepatitis, 2016-2026, $ mn 53
Figure 26. North America Preventive Vaccines Market: Vaccines for Influenza, 2016-2026, $ mn 54
Figure 27. North America Preventive Vaccines Market: Vaccines for Measles, Mumps, and Rubella (MMR), 2016-2026, $ mn 55
Figure 28. North America Preventive Vaccines Market: Vaccines for Varicella, 2016-2026, $ mn 56
Figure 29. North America Preventive Vaccines Market: Vaccines for Human Papilloma Virus, 2016-2026, $ mn 57
Figure 30. North America Preventive Vaccines Market: Vaccines for COVID-19, 2016-2026, $ mn 58
Figure 31. North America Preventive Vaccines Market: Vaccines for Other Diseases, 2016-2026, $ mn 59
Figure 32. Breakdown of North America Preventive Vaccines Market by Administration, 2019-2026, % of Revenue 61
Figure 33. Contribution to North America 2020-2026 Cumulative Revenue by Administration, Value ($ mn) and Share (%) 61
Figure 34. North America Preventive Vaccines Market: Intramuscular Route, 2016-2026, $ mn 62
Figure 35. North America Preventive Vaccines Market: Subcutaneous Route, 2016-2026, $ mn 63
Figure 36. North America Preventive Vaccines Market: Oral Route, 2016-2026, $ mn 64
Figure 37. North America Preventive Vaccines Market: Intravenous Injection, 2016-2026, $ mn 65
Figure 38. North America Preventive Vaccines Market: Other Administration Routes, 2016-2026, $ mn 66
Figure 39. Breakdown of North America Preventive Vaccines Market by Patient, 2019-2026, % of Revenue 67
Figure 40. Contribution to North America 2020-2026 Cumulative Revenue by Patient, Value ($ mn) and Share (%) 68
Figure 41. North America Preventive Vaccines Market: Pediatric Vaccines, 2016-2026, $ mn 69
Figure 42. North America Preventive Vaccines Market: Adult Vaccines, 2016-2026, $ mn 71
Figure 43. Breakdown of North America Preventive Vaccines Market by Country, 2019 and 2026, % of Revenue 74
Figure 44. Contribution to North America 2020-2026 Cumulative Revenue by Country, Value ($ mn) and Share (%) 75
Figure 45. U.S. Preventive Vaccines Market, 2016-2026, $ mn 77
Figure 46. Canada Preventive Vaccines Market, 2016-2026, $ mn 81
Figure 47. Preventive Vaccines Market in Mexico, 2016-2026, $ mn 84
Figure 48. Growth Stage of North America Preventive Vaccines Industry over the Forecast Period 87


List of Tables


Table 1. Snapshot of North America Preventive Vaccines Market in Balanced Perspective, 2019-2026 17
Table 2. Growth Rate of World Real GDP, 2017-2021 22
Table 3. Main Product Trends and Market Opportunities in North America Preventive Vaccines Market 32
Table 4. North America Preventive Vaccines Market by Vaccine Type, 2016-2026, $ mn 40
Table 5. North America Preventive Vaccines Market by Disease, 2016-2026, $ mn 49
Table 6. North America Preventive Vaccines Market by Administration, 2016-2026, $ mn 60
Table 7. North America Preventive Vaccines Market by Patient, 2016-2026, $ mn 67
Table 8. North America Preventive Vaccines Market: Pediatric Vaccines by Disease, 2016-2026, $ mn 70
Table 9. North America Preventive Vaccines Market: Adult Vaccines by Disease, 2016-2026, $ mn 72
Table 10. North America Preventive Vaccines Market by Country, 2016-2026, $ mn 74
Table 11. U.S. Preventive Vaccines Market by Vaccine Type, 2016-2026, $ mn 78
Table 12. U.S. Preventive Vaccines Market by Disease, 2016-2026, $ mn 78
Table 13. U.S. Preventive Vaccines Market by Administration, 2016-2026, $ mn 79
Table 14. Canada Preventive Vaccines Market by Vaccine Type, 2016-2026, $ mn 82
Table 15. Canada Preventive Vaccines Market by Disease, 2016-2026, $ mn 82
Table 16. Canada Preventive Vaccines Market by Administration, 2016-2026, $ mn 83
Table 17. Mexico Preventive Vaccines Market by Vaccine Type, 2016-2026, $ mn 85
Table 18. Mexico Preventive Vaccines Market by Disease, 2016-2026, $ mn 85
Table 19. Mexico Preventive Vaccines Market by Administration, 2016-2026, $ mn 86
Table 20. AstraZeneca plc: Company Snapshot 91
Table 21. AstraZeneca plc: Business Segmentation 91
Table 22. AstraZeneca plc: Product Portfolio 92
Table 23. AstraZeneca plc: Revenue, 2016-2018, $ mn 92
Table 24. AstraZeneca plc: Recent Developments 92
Table 25. Risk Evaluation for Investing in North America Market, 2019-2026 106
Table 26. Critical Success Factors and Key Takeaways 109